Group 1: New Product Development - The company has five new raw materials registered, with two completed in 2025: "Feruloyl Tripeptide-129 Amide" and "Acetylated Tyrosine Cyclic D-Glutamyl Tripeptide-110 Amide" [1] - The company plans to develop products based on these new raw materials to enhance its product matrix [1] Group 2: Sales Performance and Outlook - The company has optimized its offline sales channels and management team in 2025, laying a solid foundation for 2026 [1] - The company is optimistic about both online and offline performance in 2026, although actual results will depend on operational data [1] Group 3: Product Progress and Clinical Trials - The recombinant type III humanized collagen freeze-dried fibers have completed clinical trials and are preparing to submit application materials [2] - The injectable recombinant type III humanized collagen gel aims to start clinical trials this year [2] Group 4: Sales Channels and Profitability - The company's offline sales channels are categorized into professional channels, CS channels, KA channels, and OTC channels [2] - The company anticipates a recovery in net profit margins due to the optimization of offline sales channels, which typically have higher margins compared to online [2] Group 5: Dividend Plans - The company's dividend plan for 2026 is not yet determined, with further announcements expected on April 23, 2026 [2] - The company is committed to returning value to investors through cash dividends, contingent on 2025 performance and 2026 funding plans [2]
敷尔佳(301371) - 2026年3月11日投资者关系活动记录表（三）